EW vs VRTX
EW: Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | EW | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $87.27 | $477.08 | |
| Market cap as of 2026-07-16 | $50.9B | $120.5B | |
| P/E as of 2026-07-16 | 46.42 | 27.78 | VRTX lower |
| PEG as of 2026-07-16 | 2.13 | 2.31 | EW lower |
| Net margin as of 2026-07-16 | +17.4% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-16 | +77.9% | +86.2% | VRTX higher |
| Operating margin as of 2026-07-16 | +17.1% | +38.3% | VRTX higher |
| ROE as of 2026-07-16 | +10.6% | +23.9% | VRTX higher |
| ROA as of 2026-07-16 | +8.2% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-16 | 0.06 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-07-16 | +13.8% | +10.1% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +10.4% | EW higher |
| Beta as of 2026-07-16 | 0.83 | 0.29 | |
| 1-year return as of 2026-07-15 close | +15.1% | +2.8% | EW higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.